Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01669798 · ClinicalTrials.gov registry record · Phase 2
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
A Phase 2 study, sponsored by AA Secord.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01669798 is a Phase 2 study that has completed, run by AA Secord. The registered enrollment target is 32 participants.
The verdict
NCT01669798, a Phase 2 study, has completed, sponsored by AA Secord.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The main purpose of this study is to see if BIBF 1120 can increase the number of women with bevacizumab resistant, persistent, or recurrent epithelial ovarian cancer who do not progress for at least six months.
Interventions
- DRUG BIBF 1120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-02 |
| Est. Completion | 2018-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01669798
The ClinicalTrials.gov registry entry for NCT01669798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AA Secord, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIBF 1120 is the first listed.
NCT01669798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01669798 about?
NCT01669798 is a clinical study titled "BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer". The main purpose of this study is to see if BIBF 1120 can increase the number of women with bevacizumab resistant, persistent, or recurrent epithelial ovarian cancer who do not progress for at least six months.
What is the current status of trial NCT01669798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2013-02. Estimated completion is 2018-02.
What interventions are being tested in trial NCT01669798?
The interventions under investigation include: BIBF 1120 (DRUG).
Who is sponsoring clinical trial NCT01669798?
This trial is sponsored by AA Secord, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.